secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001558370-24-016391
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models
--------------------------------------------------------------------------------

- BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.
- Data confirm mechanism of action via insulin/PI3K/AKT pathway; supports BP1001-A as obesity/T2D treatment.
- Animal studies initiated; if successful, Phase 1 clinical trial planned for 2025.
- CEO cites unmet need from existing weight-loss drugs failing in obese T2D patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/0001558370-24-016391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/bpth-20241219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer